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Abstract
Maize MON 89034 9 1507 9 MON 88017 9 59122 9 DAS-40278-9 (ﬁve-event stack maize) was
produced by conventional crossing to combine ﬁve single events: MON 89034, 1507, MON 88017, 59122
and DAS-40278-9. The GMO Panel previously assessed the 5 single maize events and 11 of their
subcombinations and did not identify safety concerns. No new data on the single maize events or their
11 subcombinations that could modify the original conclusions on their safety were identiﬁed. The
molecular characterisation, comparative analysis (agronomic, phenotypic and compositional
characteristics) and the outcome of the toxicological, allergenicity and nutritional assessment indicates
that the combination of the single maize events and of the newly expressed proteins in the ﬁve-event
stack maize does not give rise to food and feed safety and nutritional concerns. The GMO
Panel concludes that the ﬁve-event stack maize, as described in this application, is as safe as and
nutritionally equivalent to its non-GM comparator and the non-GM reference varieties tested. In the case
of accidental release of the ﬁve-event stack maize into the environment, this would not raise
environmental safety concerns. The GMO Panel assessed the likelihood of interactions among the single
events in the 14 maize subcombinations for which no experimental data were provided, and concludes
that they are expected to be as safe as and nutritionally equivalent to the single events, the previously
assessed subcombinations and the ﬁve-event stack maize. The post-market environmental monitoring
plan and reporting intervals are in line with the intended uses of the ﬁve-event stack maize. No post-
market monitoring of food/feed is considered necessary. The GMO Panel concludes that the ﬁve-event
stack maize and its subcombinations are as safe as its non-GM comparator and the tested non-GM
reference varieties with respect to potential effects on human and animal health and the environment.
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Summary
Following the submission of application EFSA-GMO-NL-2013-113 under Regulation (EC) No 1829/2003
from Dow Agrosciences, the Panel on Genetically Modiﬁed Organisms of the European Food Safety
Authority (hereafter referred to as the ‘GMO Panel’) was asked to deliver a scientiﬁc opinion on genetically
modiﬁed (GM) maize MON 89034 9 1507 9 MON 88017 9 59122 9 DAS-40278-9 and its
subcombinations independently of their origin (referred to hereafter as ‘subcombinations’). The scope of
application EFSA-GMO-NL-2013-113 is for the placing on the market of maize MON 89034 9
1507 9 MON 88017 9 59122 9 DAS-40278-9 and all its subcombinations independently of their origin
for food and feed uses, import and processing.
The term ‘subcombination’ refers to any combination of up to four of the events present in the ﬁve-
event stack maize. The safety of subcombinations occurring as segregating progeny in the harvested
grains of maize MON 89034 9 1507 9 MON 88017 9 59122 9 DAS-40278-9 is evaluated in the
context of the assessment of the ﬁve-event stack maize in Section 3.3 of the present GMO
Panel scientiﬁc opinion. The safety of the subcombinations that either have been or could be produced
by conventional crossing through targeted breeding approaches, which can be bred, produced and
marketed independently of the ﬁve-event stack maize, are risk assessed in Section 3.4 of the present
scientiﬁc opinion.
In delivering its Scientiﬁc Opinion, the GMO Panel considered the data available on the single
events, the ﬁve-event stack maize, 11 subcombinations (six-two-event stacks, four-three-event stacks
and one-four-event stack), the scientiﬁc comments submitted by the Member States and the relevant
scientiﬁc literature. The ﬁve-event stack maize was produced by conventional crossing to combine ﬁve
single maize events: MON 89034 (expressing the Cry1A.105 and Cry2Ab2 proteins); 1507 (expressing
the Cry1F and phosphinothricin acetyltransferase (PAT) proteins); MON 88017 (expressing the Cry3Bb1
and 5-enolpyruvylshikimate-3-phosphate synthase (CP4-EPSPS) proteins); 59122 (expressing the
Cry34Ab1, Cry35Ab1 and PAT proteins); and DAS-40278-9 (expressing the aryloxyalkanoate
dioxygenase 1 (AAD-1) protein). Herbicidal tolerance traits are achieved by the expression of AAD-1
protein from Sphingobium herbicidovorans, CP4 EPSPS protein from Agrobacterium tumefaciens sp.
strain CP4, and PAT protein from Streptomyces viridochromogenes. Insecticidal resistance traits are
achieved by the expression of Cry1A.105, Cry2Ab2 and Cry1F proteins from Bacillus thuringiensis,
which confer protection against speciﬁc lepidopteran pests, and through the expression of Cry3Bb1,
Cry34Ab1 and Cry35Ab1 proteins derived from B. thuringiensis that provides protection against corn
rootworm (Diabrotica spp.) larval feeding.
The GMO Panel evaluated the ﬁve-event stack maize and its subcombinations with reference to the
scope and appropriate principles described in its guidelines for the risk assessment of GM plants and
derived food and feed, the environmental risk assessment of GM plants and the post-market
environmental monitoring (PMEM) of GM plants.
For application EFSA-GMO-NL-2013-113, previous assessments of the 5 single maize events MON
89034, 1507, MON 88017, 59122 and DAS-40278-9 and 11 subcombinations (six-two-event stacks,
four-three-event stacks and one-four-event stack), provided a basis to evaluate the ﬁve-event stack
maize and all its subcombinations. No concerns on their safety were identiﬁed by the GMO Panel in the
previous assessments. No safety issue concerning the ﬁve single maize events was identiﬁed by the
updated bioinformatic analyses, nor reported by the applicant since the publication of the previous
GMO Panel scientiﬁc opinions. Therefore, the GMO Panel considers that its previous conclusions on the
safety of the single maize events remain valid.
For the ﬁve-event stack maize, the risk assessment included the molecular characterisation of the
inserted DNA and analysis of protein expression. An evaluation of the comparative analyses of
agronomic/phenotypic and compositional characteristics was undertaken, and the safety of the newly
expressed proteins and the whole food and feed were evaluated with respect to potential toxicity,
allergenicity and nutritional characteristics. An evaluation of environmental impacts and the PMEM plan
was also undertaken.
The molecular characterization data establish that the events stacked in maize MON 89034 9
1507 9 MON 88017 9 59122 9 DAS-40278-9 have retained their integrity. Protein expression analyses
show that the levels of the newly expressed proteins are similar in the ﬁve-event stack and in the single
events or already assessed four-event stack. No indications of interactions that may affect the integrity of
the events and the levels of the newly expressed proteins in this ﬁve-event stack maize are identiﬁed.
The comparative analysis of forage and grain composition and agronomic/phenotypic characteristics
identiﬁes no differences between maize MON 89034 9 1507 9 MON 88017 9 59122 9 DAS-40278-9
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and the non-GM comparator requiring further assessment for food and feed safety or environmental
impact, except for the changes in levels of protein, glutamic acid, glycine, leucine, lysine, threonine,
magnesium and manganese in grain and the endpoint disease incidence which were further assessed
and not found to have a safety impact.
The molecular characterisation, comparative analysis (agronomic, phenotypic and compositional
characteristics) and the outcome of the toxicological, allergenicity and nutritional assessment indicate
that the combination of the single maize events and of the newly expressed proteins in the ﬁve-event
stack maize does not give rise to food and feed safety and nutritional concerns. The GMO
Panel concludes that maize MON 89034 9 1507 9 MON 88017 9 59122 9 DAS-40278-9, as described
in this application, is as safe as and nutritionally equivalent to its non-GM comparator and the non-GM
reference varieties tested.
Considering the events combined and their potential interactions, the outcome of the comparative
analysis, and the routes and levels of exposure, the GMO Panel concludes that maize
MON 89034 9 1507 9 MON 88017 9 59122 9 DAS-40278-9 would not raise safety concerns in the
case of accidental release of viable GM maize grains into the environment.
Since no new safety concerns have been identiﬁed for the previously assessed 11 subcombinations
(six-two-event stacks, four-three-event stack and one-four-event stack), the GMO Panel considers that
its previous conclusions on these maize subcombinations remain valid. For the remaining 14
subcombinations included in the scope of application EFSA-GMO-NL-2013-113 for which no
experimental data have been provided, the GMO Panel assessed the possibility of interactions between
the events and concludes that these combinations would not raise safety concerns. These
subcombinations are therefore expected to be as safe as and nutritionally equivalent to the maize
single events, the previously assessed subcombinations and the ﬁve-event stack maize.
Given the absence of safety concerns for foods and feeds from maize MON 87427 9
MON 89034 9 1507 9 MON 88017 9 59122 and all its subcombinations, the GMO Panel considers
that post-market monitoring of these products is not necessary. The PMEM plan and reporting intervals
are in line with the intended uses of the ﬁve-event stack maize and its subcombinations.
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1. Introduction
The scope of application EFSA-GMO-NL-2013-113 is for food and feed uses, import and processing in
the European Union (EU) of the genetically modiﬁed (GM) herbicide-tolerant insect-resistant maize
MON 89034 9 1507 9 MON 88017 9 59122 9 DAS-40278-9 and all its subcombinations independently
of their origin.
1.1. Background
On 6 February 2013, the European Food Safety Authority (EFSA) received from the Competent
Authority of the Netherlands application EFSA-GMO-NL-2013-113 for authorisation of maize
MON 89034 9 1507 9 MON 88017 9 59122 9 DAS-40278-9 (hereafter referred to as ‘the ﬁve-event
stack maize’) (Unique Identiﬁer MON-89Ø34-3 9 DAS-Ø15Ø7-1 9 MON-88Ø17-3 9 DAS-59122-7 9
DAS-4Ø278-9), submitted by Dow AgroSciences (hereafter referred to as ‘the applicant’) according to
Regulation (EC) No 1829/20031.
Following receipt of application EFSA-GMO-NL-2013-113, EFSA informed EU Member States and the
European Commission, and made the application available to them. Simultaneously, EFSA published
the summary of the application.2
EFSA checked the application for compliance with the relevant requirements of Regulation (EC)
No 1829/2003 and, when needed, asked the applicant to supplement the initial application. On
2 October 2014, EFSA declared the application valid.
From the validity date, EFSA and its scientiﬁc Panel on Genetically Modiﬁed Organisms (hereafter
referred to as ‘the GMO Panel’) endeavoured to respect a time limit of six months to issue a scientiﬁc
opinion on application EFSA-GMO-NL-2013-113. Such time limit was extended whenever EFSA and/or
its GMO Panel requested supplementary information to the applicant. According to Regulation (EC)
No 1829/2003, any supplementary information provided by the applicant during the risk assessment
was made available to the EU Member States and European Commission (for further details, see the
section ‘Documentation’, below).
In accordance with Regulation (EC) No 1829/2003, EFSA consulted the nominated risk assessment
bodies of EU Member States, including national Competent Authorities within the meaning of Directive
2001/18/EC3. The EU Member States had three months to make their opinion known on application
EFSA-GMO-NL-2013-113 as of date of validity.
1.2. Terms of Reference as provided by the requestor
According to Articles 6 and 18 of Regulation (EC) No 1829/2003, EFSA and its GMO Panel were
requested to carry out a scientiﬁc risk assessment of the ﬁve event stack maize and all its
subcombinations independently of their origin, for food and feed uses, import and processing.
According to Regulation (EC) No 1829/2003, this scientiﬁc opinion is to be seen as the report
requested under Articles 6(6) and 18(6) of that Regulation and thus will be part of the EFSA overall
opinion in accordance with Articles 6(5) and 18(5).
In addition to the present scientiﬁc opinion, EFSA was also asked to report on the particulars listed
under Articles 6(5) and 18(5) of Regulation (EC) No 1829/2003, but not to give an opinion on them,
because they pertain to risk management.4
2. Data and methodologies
2.1. Data
The GMO Panel based its scientiﬁc assessment of the ﬁve-event stack maize on the valid application
EFSA-GMO-NL-2013-113, additional information provided by the applicant during the risk assessment,
relevant scientiﬁc comments submitted by EU Member States and relevant peer-reviewed scientiﬁc
publications.
1 Regulation (EC) No 1829/2003 of the European Parliament and of the Council of 22 September 2003 on genetically modiﬁed
food and feed. OJ L 268, 18.10.2003, p. 1–23.
2 Available online: http://registerofquestions.efsa.europa.eu/roqFrontend/questionLoader?question=EFSA-Q-2013-00989
3 Directive 2001/18/EC of the European Parliament and of the Council of 12 March 2001 on the deliberate release into the
environment of genetically modiﬁed organisms and repealing Council Directive 90/220/EEC. OJ L 106, 12.3.2001, p. 1–38.
4 These particulars can be found in the technical report by EFSA on the application EFSA-GMO-NL-2013-113, made available in
the EFSA Register of Questions.
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2.2. Methodologies
The GMO Panel conducted its assessment in line with the principles described in Regulation (EU)
No 1829/2003, its applicable guidelines (i.e. EFSA GMO Panel, 2010a, 2011a,b) and explanatory notes
(i.e. EFSA, 2017a,b) for the risk assessment of GM plants.
In the context of the contracts OC/EFSA/GMO/2013/01 and OC/EFSA/GMO/2014/01, contractors
performed preparatory work and delivered reports on the methods applied by the applicant in
performing bioinformatic and statistical analyses, respectively.
3. Assessment
3.1. Introduction
Application EFSA-GMO-NL-2013-113 covers the ﬁve-event stack maize MON 89034 9
1507 9 MON 88017 9 59122 9 DAS-40278-9 and all its subcombinations independently of their origin
(Table 1).
The term ‘subcombination’ refers to the speciﬁc combinations of up to four of the events present in
the ﬁve-event stack maize.
The safety of subcombinations occurring as segregating progeny in the harvested grains of the ﬁve-
event stack maize is evaluated in the context of the assessment of the ﬁve-event stack maize in
Section 3.3 of the present GMO Panel scientiﬁc opinion.
‘Subcombination’ also covers combinations of up to four of the ﬁve events MON 89034, 1507,
MON 88017, 59122 and DAS-40278-9 that have either been, or could be produced by conventional
crossing through targeted breeding approaches (EFSA GMO Panel, 2011a). These are maize stacks
that can be bred, produced and marketed independently of the ﬁve-event stack maize. These
subcombinations are risk assessed in the Section 3.4 of this scientiﬁc opinion.
The ﬁve-event stack maize was produced by conventional crossing to combine ﬁve single maize
events: MON 89034 (expressing the Cry1A.105 and Cry2Ab2 proteins); 1507 (expressing the Cry1F
and phosphinothricin acetyl transferase (PAT) proteins); MON 88017 (expressing the Cry3Bb1 and
5-enolpyruvylshikimate-3-phosphate synthase (CP4-EPSPS) proteins); 59122 (expressing the Cry34Ab1,
Cry35Ab1 and PAT proteins); and DAS-40278-9 (expressing the aryloxyalkanoate dioxygenase 1
(AAD-1) protein).
Herbicidal tolerance traits are achieved by the expression of AAD-1 protein from Sphingobium
herbicidovorans, CP4 EPSPS protein from Agrobacterium tumefaciens sp. strain CP4 and PAT protein
from Streptomyces viridochromogenes. Insecticidal resistance traits are achieved by the expression of
Cry1A.105, Cry2Ab2 and Cry1F proteins from Bacillus thuringiensis, which confer protection against
speciﬁc lepidopteran pests, and through the expression of Cry3Bb1, Cry34Ab1 and Cry35Ab1 proteins
derived from B. thuringiensis that provides protection against corn rootworm (Diabrotica spp.) larval
feeding.
Table 1: Stacked maize events covered by the scope of application EFSA-GMO-NL-2012-113
Degree of stacking Events
Five-event stack maize MON 89034 9 1507 9 MON 88017 9 59122 9 DAS-40278-9
Four-event stack maize MON 89034 9 1507 9 MON 88017 9 59122
MON 89034 9 1507 9 MON 88017 9 DAS-40278-9
MON 89034 9 1507 9 59122 9 DAS-40278-9
MON 89034 9 MON 88017 9 59122 9 DAS-40278-9
1507 9 MON 88017 9 59122 9 DAS-40278-9
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All ﬁve single maize events MON 89034, 1507, MON 88017, 59122 and DAS-40278-9 and 11
subcombinations (six-two-event stacks, four-three-event stack and one-four-event stack) have been
previously assessed (see Table 2). No concerns for human and animal health, or environmental safety
were identiﬁed.
Degree of stacking Events
Three-event stack maize MON 89034 9 1507 9 MON 88017
MON 89034 9 1507 9 59122
MON 89034 9 1507 9 DAS-40278-9
MON 89034 9 MON 88017 9 59122
MON 89034 9 MON 88017 9 DAS-40278-9
MON 89034 9 59122 9 DAS-40278-9
1507 9 MON 88017 9 59122
1507 9 MON 88017 9 DAS-40278-9
1507 9 59122 9 DAS-40278-9
MON 88017 9 59122 9 DAS-40278-9
Two-event stack maize MON 89034 9 1507
MON 89034 9 MON 88017
MON 89034 9 59122
MON 89034 9 DAS-40278-9
1507 9 MON 88017
1507 9 59122
1507 9 DAS-40278-9
MON 88017 9 59122
MON 88017 9 DAS-40278-9
59122 9 DAS-40278-9
Table 2: Single maize events and subcombinations of maize MON 89034 9 1507 9
MON 88017 9 59122 9 DAS-40278-9 previously assessed by the GMO Panel
Event
Application or
mandate
EFSA Scientiﬁc Opinion
MON 89034 EFSA-GMO-NL-2007-37 EFSA (2008)
1507 C/NL/00/10 EFSA (2004)
C/ES/01/01 EFSA (2005a)
EFSA-GMO-NL-2004-02 EFSA (2005b)
EFSA-GMO-RX-1507 EFSA (2009a)
EFSA-M-2012-0231(a) EFSA GMO Panel (2012)
EFSA GMO-RX-001 EFSA GMO Panel (2017a)
MON 88017 EFSA-GMO-NL-2005-27 EFSA (2009b)
59122 EFSA-GMO-NL-2005-12 EFSA (2007)
EFSA-GMO-NL-2005-23 EFSA (2013)
DAS-40278-9 EFSA GMO NL 2010-89 EFSA GMO Panel (2016a)
MON 89034 9 MON 88017 EFSA-GMO-NL-2007-39 EFSA (2010)
MON 89034 9 1507 EFSA-GMO-NL-2009-65 EFSA GMO Panel (2011c)
1507 9 59122 EFSA-GMO-NL-2005-15 EFSA (2009c)
MON 89034 9 1507 9 MON 88017 9 59122
(and its 10 subcombinations)
EFSA-GMO-CZ-2008-62
EFSA-GMO-BE-2013-118
EFSA GMO Panel (2010c, 2011d);
EFSA GMO Panel (2017b)
(a): Available online: http://registerofquestions.efsa.europa.eu/roqFrontend/questionLoader?question=EFSA-Q-2012-00712
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3.2. Updated information on the single events5
Since the publication of the GMO Panel scientiﬁc opinions on the ﬁve single maize events (Table 2),
no safety issue concerning the ﬁve single events has been reported by the applicant.
The applicant clariﬁed that the 1507 maize sequence reported for the ﬁve-event stack maize
contained one silent nucleotide change in the insert sequence compared to the corrected original 1507
maize sequence (EFSA GMO Panel, 2018a,b). Analysis of the new sequencing data and bioinformatic
analyses performed on the new sequence does not identify any need for further safety assessment.
In addition, the applicant clariﬁed that the maize 59122 sequence reported in this application
corresponds to the sequence submitted in the original application EFSA-GMO-NL-2005-12 of the single
event (EFSA GMO Panel, 2016b), but corrected for sequencing errors affecting three single
nucleotides. Analysis of the corrected sequencing data and the bioinformatic analyses performed on
this sequence did not give rise to safety issues (EFSA GMO Panel, 2016b).
Updated bioinformatic analyses on the junction regions for maize events MON 89034, 1507, MON
88017, 59122 and DAS-40278-9, using the methodology speciﬁed in the 2011 GMO Panel Guidance
Document (EFSA GMO Panel, 2011a) conﬁrm that no known endogenous genes were disrupted by any
of the inserts.
Updated bioinformatic analyses of the amino acid sequence of the newly expressed Cry1A.105,
Cry2Ab2, Cry1F, Cry3Bb1, Cry34Ab1, Cry35Ab1, PAT, CP4-EPSPS and AAD-1 proteins reveal no
signiﬁcant similarities to toxins and allergens. Updated bioinformatic analyses of the newly created
open reading frames (ORFs) within the insert or spanning the junctions between the insert and
genomic DNA indicate that the expression of an ORF showing signiﬁcant similarities to toxins or
allergens is highly unlikely.
In order to assess the possibility for horizontal gene transfer (HGT) by homologous recombination,
the applicant performed a sequence identity analysis for maize events MON 89034, 1507, MON 88017,
59122 and DAS-40278-9, with microbial DNA. The likelihood and potential consequences of plant-to-
bacteria gene transfer are described in Section 3.3.4.2.
Based on the above information, the GMO Panel considers that its previous conclusions on the
safety of the single maize events remain valid.
3.3. Risk assessment of the ﬁve-event maize MON 89034 3 1507 3
MON 88017 3 59122 3 DAS-40278-9
3.3.1. Molecular characterisation6
Possible interactions that would affect the integrity of the events, newly expressed proteins levels
or the biological function conferred by the individual inserts are considered below.
3.3.1.1. Genetic elements and their biological function
Maize events MON 89034, 1507, MON 88017, 59122 and DAS-40278-9 were combined by
conventional crossing to produce the ﬁve-event stack maize. The structure of the inserts in the ﬁve-
event stack is described in detail in the respective EFSA scientiﬁc opinions (Table 2) and no new
genetic modiﬁcations were involved. Genetic elements in the expression cassettes of the single events
are summarised in Table 3. Intended effects of the inserts in the ﬁve-event stack maize are
summarised in Table 4.
Based on the known biological function of the newly expressed proteins (Table 4), the only
foreseen interactions at the biological level are between the six Cry proteins in susceptible insects.
5 Dossier: Part II Scientiﬁc information, Section 2.2.2., and additional information 22/4/2015, 13/10/2016, 21/10/2016, 25/1/
2017, 7/2/2017, 24/11/2017, 12/3/2018, 31/10/2018 and 20/11/2018.
6 Dossier: Part II Scientiﬁc information, Section 2, and additional information 7/2/2017.
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Table 3: Genetic elements in the expression cassettes of the events stacked in maize MON 89034 9
1507 9 MON 88017 9 59122 9 DAS-40278-9
Event Promoter 50 UTR Transit peptide Coding region* Terminator
MON 89034 35S (CaMV) CAB (Triticum
sp.)
– cry1A.105 (Bacillus
thuringiensis)
Hsp17 (Triticum
sp.)
35S (FMV) – CTP (Zea mays) cry2Ab2
(B. thuringiensis)
nos (Agrobacterium
tumefaciens)
1507(a) ubiZM1 (Z. mays) – – cry1F (B. thuringiensis) ORF25PolyA
(A. tumefaciens)
35S (CaMV) – – pat (Streptomyces
viridochromogenes)
35S (CaMV)
MON 88017 act1 (Oryza sativa) – CTP2
(Arabidopsis
thaliana)
CP4 epsps
(Agrobacterium sp.)
nos
(A. tumefaciens)
35S (CaMV) CAB (Triticum
sp.)
– cry3Bb1
(B. thuringiensis)
hsp17 (Triticum sp)
59122 ubiZM1 (Z. mays) – – cry34Ab1
(B. thuringiensis)
pinII (Solanum
tuberosum)
Wheat peroxidase
(Triticum aestivum)
– – cry35Ab1
(B. thuringiensis)
pinII
(S. tuberosum)
35S (CaMV) – – pat
(S. viridochromogenes)
35S (CaMV)
DAS-40278-
9
ZmUbi1 (Z. mays) – – aad-1 (Sphingobium
herbicidovorans)
ZmPer5 30 UTR
(Z. mays)
CaMV: Cauliﬂower Mosaic Virus; FMV: Figwort Mosaic Virus.
*: All gene sequences are codon-optimised for expression in plants.
–: When no element was speciﬁcally introduced to optimise expression.
(a): Maize 1507 also contains partial fragments of the cry1F and pat genes at a single locus in the nuclear genome.
Table 4: Characteristics and intended effects of the events stacked in maize MON 89034 9 1507 9
MON 88017 9 59122 9 DAS-40278-9
Event Protein Donor organism and biological function Intended effects in GM plant
MON
89034
Cry1A.105 Based on genes from Bacillus thuringiensis subsp.
kurstaki and subsp. aizawai. B. thuringiensis is an
insect pathogen; its insecticidal activity is attributed
to the expression of crystal protein (cry) genes
(Schnepf et al., 1998; Ellis et al., 2002)
Event MON89034 expresses a
modiﬁed version of the Cry1A-type
protein. Cry1A.105 is a protein toxic
to certain lepidopteran larvae feeding
on maize
Cry2Ab2 Based on a gene from Bacillus thuringiensis subsp.
kurstaki. B. thuringiensis an insect pathogen; its
insecticidal activity is attributed to the expression of
crystal protein (cry) genes (Schnepf et al., 1998;
Ellis et al., 2002)
Event MON 89034 expresses the
Cry2Ab2, a protein toxic to certain
lepidopteran larvae feeding on maize
1507 Cry1F Based on a gene from Bacillus thuringiensis subsp.
aizawai. B. thuringiensis is an insect pathogen; its
insecticidal activity is attributed to the expression of
crystal protein (cry) genes (Schnepf et al., 1998;
Ellis et al., 2002)
Event 1507 expresses a truncated
version of the Cry1F protein. Cry1F is
a protein toxic to certain lepidopteran
larvae feeding on maize
PAT Based on a gene from Streptomyces
viridochromogenes T€u494. Phosphinothricin-acetyl-
transferase (PAT) enzyme acetylates L-glufosinate-
ammonium (Thompson et al., 1987; Wohlleben
et al., 1988; Eckes et al., 1989)
Event 1507 expresses the PAT protein
which confers tolerance to
glufosinate-ammonium-based
herbicides (Droge-Laser et al., 1994)
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3.3.1.2. Integrity of the events in the ﬁve-event stack maize
The genetic stability of the inserted DNA over multiple generations in the single maize events MON
89034, 1507, MON 88017, 59122 and DAS-40278-9 was previously demonstrated (see Table 2).
Integrity of these events in the ﬁve-event stack maize was demonstrated by Southern analyses.
3.3.1.3. Information on the expression of the inserts
Cry1A.105, Cry2Ab2, Cry1F, Cry3Bb1, Cry34Ab1, Cry35Ab1, PAT, CP4EPSPS and AAD-1 protein
levels were analysed by enzyme-linked immunosorbent assay (ELISA) in material harvested from a
ﬁeld trial across 10 locations in the US in 2010. The ﬁve-event stack maize samples analysed included
leaf (V2–V4, V9), root (R1), grain (R6), pollen (R1), forage (R4) and whole plant (R6) treated and not
treated with intended herbicides. The applicant indicated that a small percentage of the non-GM
controls showed detectable levels of the proteins, possibly resulting from cross-contamination or
sampling error. Additional information requested by the GMO Panel did not allow limiting this
observation to particular locations. Considering that the proportion of contaminated controls was very
low and given the high number of samples analysed, the impact on the mean expression values
presented in Appendix 1 is considered negligible.
In order to assess changes in protein expression levels which may result from potential interactions
between the events, protein levels were determined for the ﬁve-event stack maize and one
corresponding single events or the already assessed four-event stack maize MON 89034 9 1507 9
MON 88017 9 DAS-59122-7 (see Table 2) in different parts of the plant grown without intended
herbicide regimes.
The levels of the proteins in the ﬁve-event stack maize were comparable in all tissues to those of
either the single event DAS-40278-9 or the previously assessed four-event stack MON 89034 9 1507 9
MON 88017 9 DAS-59122-7 (EFSA GMO Panel, 2010c, Appendix 1).Therefore, there is no indication of
Event Protein Donor organism and biological function Intended effects in GM plant
MON
88017
CP4 EPSPS Based on a gene from Agrobacterium strain CP4. 5-
Enolpyruvylshikimate-3-phosphate synthase (EPSPS)
is an enzyme involved in the shikimic acid pathway
for aromatic amino acid biosynthesis in plants and
microorganisms (Herrmann, 1995)
Event MON 88017 expresses the
bacterial CP4 EPSPS protein which
confers tolerance to glyphosate-based
herbicides as it has lower afﬁnity
towards glyphosate than the plant
endogenous enzyme
Cry3Bb1 Based on a gene from Bacillus thuringiensis subsp.
kumamotoensis. B. thuringiensis is an insect
pathogen; its insecticidal activity is attributed to the
expression of crystal protein (cry) genes (Schnepf
et al., 1998; Ellis et al., 2002)
Event MON 88017 expresses the
Cry3Bb1, a protein toxic to certain
lepidopteran larvae feeding on maize
59122 Cry34Ab1 Based on a gene from Bacillus thuringiensis strain
PS149B1. B. thuringiensis is an insect pathogen; its
insecticidal activity is attributed to the expression of
crystal protein (cry) genes (Schnepf et al., 1998;
Ellis et al., 2002)
Event 59122 expresses the Cry34Ab1.
In complex with Cry35Ab1 this protein
is toxic to certain coleopteran larvae
feeding on maize
Cry35Ab1 Based on a gene from Bacillus thuringiensis strain
PS149B1. B. thuringiensis is an insect pathogen; its
insecticidal activity is attributed to the expression of
crystal protein (cry) genes (Schnepf et al., 1998;
Ellis et al., 2002)
Event 59122 expresses the Cry35Ab1.
In complex with Cry34Ab1 this protein
is toxic to certain coleopteran larvae
feeding on maize
PAT Based on a gene from Streptomyces
viridochromogenes T€u494. Phosphinothricin-acetyl-
transferase (PAT) enzyme acetylates L-glufosinate-
ammonium (Thompson et al., 1987; Wohlleben
et al., 1988; Eckes et al., 1989)
Event 59122 expresses the PAT
protein which confers tolerance to
glufosinate ammonium-based
herbicides (Droge-Laser et al., 1994)
DAS-
40278-9
AAD-1 Based on a gene from Sphingobium
herbicidovorans. Aryloxyalkanoate dioxygenase
(AAD-1) facilitates the breakdown of phenoxy auxin
and aryloxyphenoxypropionate herbicides into
carbon sources for the bacterium (Wright et al.,
2009)
Event DAS-40278-9 expresses AAD-1
protein which degrades the herbicide
2,4-dichlorophenoxyacetic acid (2,4-
D) and thus confers tolerance to this
herbicide
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interactions that may affect the integrity of the events and the levels of the newly expressed proteins in
this stack.
3.3.1.4. Conclusion on molecular characterisation
The molecular data establish that the events stacked in the ﬁve-event stack maize have retained
their integrity. Protein expression analyses show that the levels of the newly expressed proteins in the
ﬁve-event stack maize are similar to those of either the single event DAS-40278-9 or the already
assessed four-event stack maize MON 89034 9 1507 9 MON 88017 9 DAS-59122-7. Therefore, there
is no indication of an interaction that may affect the integrity of the events and the levels of the newly
expressed proteins in this stack.
Based on the known biological function of the newly expressed proteins (Table 4), the only
foreseen interactions at the biological level are between the Cry proteins in susceptible insects, which
is dealt with in Section 3.3.4.4.
3.3.2. Comparative analysis7
3.3.2.1. Choice of comparator and production of material for the comparative analysis
Application EFSA-GMO-NL-2013-113 presents data on agronomic and phenotypic characteristics, as
well as forage and grain composition of the ﬁve-event stack maize derived from ﬁeld trials performed
at 10 sites in US during the 2010 growing season (Table 5).
The ﬁve-event stack maize was obtained by conventional crossing: events MON 89034, MON 88017
and DAS-40278-9 were introgressed in the inbred line SLB01, while events 1507 and 59122 in BE9514.
As documented by the pedigree, the ﬁve single events, after backcrossing, were combined in a hybrid
maize with a genetic background (F1) of SLB01 9 BE9514. The same two inbred lines (SLB01 and
BE9514) were crossed to produce the non-GM hybrid maize used as comparator. On the basis of the
provided pedigree, documenting the production of the ﬁve-event stack GM maize, the EFSA GMO
Panel considers that the hybrid maize SLB01 9 BE9514 is a suitable comparator.
The ﬁeld trial sites were located in major maize growing areas of the US,8 representing regions of
diverse agronomic practices and environmental conditions. At each site, the following materials were
grown in a randomised complete block design with four replicates: the ﬁve-event stack maize treated,
a non-GM comparator and three non-GM reference varieties, all treated (sprayed) with plant protection
products (PPP) according to local requirements, and the ﬁve-event stack maize treated with the
intended herbicides (glyphosate-, glufosinate-ammonium-, quizalofop- and 2,4-D-containing herbicides)
in addition to the other PPP.
Statistical analysis of ﬁeld trials data
The statistical analysis of the agronomic, phenotypic and compositional data from the 2010 ﬁeld
trials followed the recommendations of the GMO Panel (EFSA GMO Panel, 2010b, 2011a). This
includes, for each of the two treatments of the ﬁve-event stack maize, the application of a difference
test (between the GM maize and non-GM comparator) and an equivalence test (between the GM
maize and the set of non-GM commercial reference varieties). The results of the equivalence test are
categorised into four possible outcomes (I–IV, ranging from equivalence to non-equivalence).9
Table 5: Overview of comparative assessment studies with the ﬁve-event stack maize
Study focus Study details Comparator
Non-GM commercial
reference varieties
Agronomic, phenotypic and
compositional analysis
Field study, 2010, US, 10 sites SLB01 9 BE9514 Six
GM: genetically modiﬁed.
7 Dossier: Part II Scientiﬁc information, Section 3.
8 Richland, Jefferson, Lime Springs and Atlantic in Iowa; Cherry Grove and Geneva in Minnesota; Wyoming, Illinois; Deerﬁeld,
Michigan; Brunswick, Nebraska and Germansville, Pennsylvania.
9 In detail, the four outcomes are: category I (indicating full equivalence to the non-GM reference varieties); category II
(equivalence is more likely than non-equivalence); category III (non-equivalence is more likely than equivalence); and category
IV (indicating non-equivalence).
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3.3.2.2. Agronomic and phenotypic analysis
A total of 26 agronomic and phenotypic endpoints, including observations on the biotic and abiotic
interactions, were analysed.10
Data for 15 endpoints11 were considered not suitable for a parametric analysis; for these a
Wilcoxon signed-rank (WSR) test was used to check for differences between the GM maize and the
non-GM comparator.
The remaining 11 endpoints were analysed as described in Section 3.3.2.1, with the following outcomes:
• For the ﬁve-event stack maize (not treated with the intended herbicides), statistically
signiﬁcant differences with the non-GM comparator were identiﬁed for early population, ﬁnal
population and disease incidence. Early population and ﬁnal population fell under equivalence
category I or II. For disease incidence,12 the test of equivalence was not applied because the
variability among the non-GM reference varieties was estimated to be zero and thus, further
assessment was needed.
• For the ﬁve-event stack maize (treated with the intended herbicides), statistically signiﬁcant
differences with the non-GM comparator were identiﬁed for early population, ﬁnal population
and time to pollen shed. All three endpoints fell under equivalence category I or II.
Of the endpoints analysed with the WSR test, a statistically signiﬁcant difference was identiﬁed for
days to maturity. However, the mean difference (in heat units) corresponded to a small fraction of a
day.
3.3.2.3. Compositional analysis
Forage and grain harvested from the ﬁeld trial study in the US in 2010 (Table 5) were analysed for
82 constituents (9 in forage and 73 in grain), including the key constituents recommended by the
OECD (OECD, 2002). For 17 grain constituents,13 more than 50% of the observations were below the
limit of quantiﬁcation. The statistical analysis was applied to the remaining 65 constituents (9 in
forage14 and 56 in grain15). A summary of the outcome of the test of difference and the test of
equivalence is presented in Table 6:
• For the ﬁve-event stack maize (not treated with the intended herbicides), statistically signiﬁcant
differences with the non-GM comparator were identiﬁed for 21 grain endpoints and phosphorus
in forage. All these endpoints fell under equivalence category I or II, except for grain content of
protein, magnesium and manganese which fell under equivalence category III or IV. Levels of
leucine, phenylalanine and ferulic acid in grain fell under equivalence category III or IV,
although no statistically signiﬁcant differences were identiﬁed with the non-GM comparator.
• For the ﬁve-event stack maize (treated with the intended herbicides), statistically signiﬁcant
differences with the non-GM comparator were identiﬁed for 31 grain endpoints and 4 forage
endpoints. All these endpoints fell under equivalence category I or II, except for levels of
protein, glutamic acid, glycine, leucine, lysine, threonine, magnesium and manganese in grain,
which fell under equivalence category III or IV. Levels of cystine, phenylalanine and iron in
grain fell under equivalence category III or IV, although no statistically signiﬁcant differences
were identiﬁed with the non-GM comparator.
10 Early population, ﬁnal population, time to silking, time to pollen shed, plant height, ear height, yield, pollen colour (measured
at 0, 30, 60 and 120 min), pollen shape (measured at 0, 30, 60 and 120 min), stay green, herbicide injury (after each of 4
herbicide applications), disease incidence, insect damage, days to maturity, root lodging, stalk lodging and seedling vigour.
11 Days to maturity, herbicide injury (at 4 time points), insect damage, pollen colour (at 0, 60 and 120 min), pollen shape (at 0,
60 and 120 min), root lodging, seedling vigour, and stalk lodging.
12 Estimated mean values for disease incidence (% plant tissue/leaf area with symptoms) were the following: 15.58% (non-GM
comparator); 19.02% (untreated GM maize); and 18.74% (non-GM commercial reference varieties).
13 Sodium, furfural, ascorbic acid and the fatty acids caprylic (8:0), capric (10:0), lauric (12:0), myristic (14:0), myristoleic
(14:1), pentadecanoic (15:0), pentadecenoic (15:1), palmitoleic (16:1), heptadecanoic (17:0), heptadecenoic (17:1),
c-linolenic (18:3), eicosadienoic (20:2), eicosatrienoic (20:3) and arachidonic (20:4).
14 Protein, fat, ash, moisture, carbohydrates, acid detergent ﬁbre (ADF), neutral detergent ﬁbre (NDF), calcium and phosphorus.
15 Proximates (protein, fat, ash, moisture and carbohydrates by calculation), ﬁbre fractions (acid detergent ﬁbre (ADF), neutral
detergent ﬁbre (NDF) and total detergent ﬁbre (TDF)), minerals (calcium, copper, iron, magnesium, manganese, phosphorus,
potassium, selenium and zinc), amino acids (alanine, arginine, aspartic acid, cystine, glutamic acid, glycine, histidine,
isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine and valine), fatty acids
((palmitic acid (16:0), stearic acid (18:0), oleic acid (18:1), linoleic acid (18:2), linolenic acid (18:3), arachidic acid (20:0),
eicosenoic acid (20:1) and behenic acid (22:0)), vitamins (b-carotene, thiamine, riboﬂavin, niacin, pyridoxine, folic acid and
a-tocopherol) and other compounds (inositol, p-coumaric acid, ferulic acid, phytic acid, rafﬁnose and trypsin inhibitor).
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The GMO Panel assessed all signiﬁcant differences between the ﬁve-event stack maize and the
non-GM comparator, taking into account potential impact on plant metabolism and the natural
variability observed for the set of non-GM commercial reference varieties. Quantitative results for the
endpoints showing signiﬁcant differences between the ﬁve-event stack maize and the non-GM
comparator and falling under category III/IV are given in Table 7.
Table 6: Outcome of the comparative compositional analysis in grains and forage of the ﬁve-stack
maize MON 89034 9 1507 9 MON 88017 9 59122 9 DAS-40278-9. The table shows the
number of endpoints in each category
Test of difference(a)
Not treated(c) Treated(c)
Not
different
Signiﬁcantly
different
Not
different
Signiﬁcantly
different
Test of
equivalence(b)
Category I/II 38 19(d) 25 27(d)
Category III/IV 3(e) 3(f) 3(e) 8(f)
Not categorised 2(g) – 2(g) –
Total endpoints 65 65
(a): Comparison between maize MON 89034 9 1507 9 MON 88017 9 59122 9 DAS-40278-9 and its non-GM comparator.
(b): Four different outcomes: category I (indicating full equivalence to the non-GM reference varieties); category II (equivalence
is more likely than non-equivalence); category III (non-equivalence is more likely than equivalence); and category IV
(indicating non-equivalence). Not categorised means that the test of equivalence was not applied because of the lack of
variation among the non-GM reference varieties.
(c): Treated/not-treated with the intended herbicides (see Section 3.3.2.1).
(d): Endpoints with signiﬁcant differences between maize MON 89034 9 1507 9 MON 88017 9 59122 9 DAS-40278-9 and its
non-GM comparator falling in equivalence category I-II (treated and not treated).
For grain, both treated and not treated: p-coumaric acid, inositol, phytic acid, palmitic acid (16:0), stearic acid (18:0), oleic
acid (18:1), linoleic acid (18:2), linolenic acid (18:3), ash, total fat, phosphorus, potassium, zinc, beta-carotene (A),
thiamine (B1) and alpha-tocopherol. For not treated only: selenium and riboﬂavin (B2). For treated only: arginine, histidine,
valine, eicosenoic acid (20:1), ferulic acid, moisture and carbohydrates.
For forage, both treated and not treated: phosphorus. For treated only: ash, carbohydrates and protein.
(e): The following endpoints in grain fell under equivalence category III or IV, although no statistically signiﬁcant differences
were identiﬁed with respect to the comparator: phenylalanine (both treated and not treated), leucine and ferulic acid (not
treated only), cystine and iron (treated only).
(f): Endpoints with signiﬁcant differences between maize MON 89034 9 1507 9 MON 88017 9 59122 9 DAS-40278-9 and its
non-GM comparator and falling in equivalence category III–IV. Quantitative results for these endpoints are reported in
Table 7.
(g): Endpoints not categorised for equivalence and with no signiﬁcant differences between maize MON 89034 9 1507 9
MON 88017 9 59122 9 DAS-40278-9 (both treated and not treated) and its non-GM comparator: isoleucine and trypsin
inhibitor in grain.
Table 7: Quantitative results (estimated means and equivalence limits) for compositional endpoints
in grain that are further assessed based on the results of the statistical analysis
Endpoint
Maize MON 89034 3 1507
3 MON 88017 3 59122 3
DAS-40278-9
Non-GM
comparator
Non-GM reference varieties
Not treated Treated(a) Mean Equivalence limits
Glutamic acid (%AA) 18.98 19.08* 18.91 18.48 (17.98, 19.00)
Glycine (%AA) 3.746 3.681* 3.776 4.026 (3.693, 4.391)
Leucine (%AA) 12.70 12.84* 12.63 12.09 (11.55, 12.67)
Lysine (%AA) 2.720 2.646* 2.772 2.967 (2.649, 3.326)
Threonine (%AA) 3.553 3.516* 3.558 3.64 (3.531, 3.752)
Protein (% dw) 11.40* 11.06* 10.73 9.53 (8.16, 10.89)
Magnesium (mg/100 g dw) 136.5* 136.6* 126.4 110.1 (89.9, 134.7)
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3.3.2.4. Conclusion on comparative analysis
Based on the agronomic and phenotypic characteristics of the ﬁve-event stack maize tested under
ﬁeld conditions, none of the differences observed between the ﬁve-event stack maize its non-GM
comparator are further assessed for potential environmental impact, except for the endpoint disease
incidence which is further assessed in Section 3.3.4.1.
The GMO Panel also concludes that none of the differences identiﬁed in forage and grain
composition between the ﬁve-event stack maize, the non-GM comparator and the non-GM commercial
reference varieties needs further assessment regarding food and feed safety, except for the changes in
levels of protein, glutamic acid, glycine, leucine, lysine, threonine, magnesium and manganese in
grain, which are further assessed in Section 3.3.3.
3.3.3. Food and feed safety assessment16
3.3.3.1. Effects of processing
The ﬁve-event stack maize will undergo existing production processes used for conventional maize.
Based on the outcome of the comparative assessment, processing of the ﬁve-event stack maize into
food and feed products is not expected to result in products being different from those of non-GM
maize varieties.
3.3.3.2. Inﬂuence of Temperature and pH on newly expressed proteins
Effects of temperature and pH on Cry1A.105, Cry2Ab2, Cry1F, Cry3Bb1, Cry34Ab1, Cry35Ab1, PAT,
CP4 EPSPS and AAD-1 proteins have been previously evaluated by the GMO Panel (Table 2). In the
context of this application, no new studies addressing these aspects were provided by the applicant.
3.3.3.3. Toxicology
Testing of newly expressed proteins
Nine proteins (Cry1A.105, Cry2Ab2, Cry1F, Cry3Bb1, Cry34Ab1, Cry35Ab1, PAT, CP4 EPSPS and
AAD-1) are newly expressed in the ﬁve-event stack maize (see Section 3.1). The GMO Panel has
previously assessed these proteins in the context of the single maize events (see Table 2), and no
safety concerns were identiﬁed for humans and animals. The GMO Panel is not aware of any new
information that would change these conclusions.
The potential for a functional interaction between the proteins newly expressed in the ﬁve-event
stack maize has been assessed with regard to human and animal health. The CP4 EPSPS, PAT and
AAD-1 proteins are enzymes that catalyse distinct biochemical reactions and act on unrelated
substrates with high substrate speciﬁcity. The Cry1A.105, Cry2Ab2, Cry3Bb1, Cry3Bb1, Cry34Ab1 and
Cry1F proteins are delta endotoxins with highly speciﬁc insecticidal properties acting through cellular
receptors found in target insect species. It is reported that the gastrointestinal tract of mammals,
including humans, lacks receptors with high afﬁnity to Cry proteins (Hammond et al., 2013; Koch
et al., 2015). On the basis of the known biological functions of the individual newly expressed proteins
(Table 4), there is currently no expectation for possible interactions relevant for the food and feed
safety of the ﬁve-event stack maize.
In vitro protein degradation studies on Cry1A.105, Cry2Ab2, Cry1F, Cry3Bb1, Cry34Ab1, Cry35Ab1,
PAT, CP4 EPSPS and AAD-1 proteins have been previously evaluated by the EFSA GMO Panel (Table 2).
Endpoint
Maize MON 89034 3 1507
3 MON 88017 3 59122 3
DAS-40278-9
Non-GM
comparator
Non-GM reference varieties
Not treated Treated(a) Mean Equivalence limits
Manganese (mg/100 g dw) 0.788* 0.834* 0.748 0.550 (0.402, 0.754)
GM: genetically modiﬁed; dw: dry weight; % AA: percentage total amino acid.
(a): Treated with the intended herbicides as described in Section 3.3.2.1.
For the GM maize, signiﬁcantly different entries are marked with an asterisk, while the outcomes of the test of equivalence are
differentiated by a greyscale background: white (equivalence category I or II), light grey (equivalence category III) and dark
grey (equivalence category IV).
16 Dossier: Part II Scientiﬁc information, Sections 4, 5 and 6.
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In the context of this application, no new studies addressing in vitro protein degradation of these
newly expressed proteins were provided by the applicant.
The GMO Panel concludes that there are no safety concerns for human and animal health related
to the newly expressed proteins Cry1A.105, Cry2Ab2, Cry1F, Cry3Bb1, Cry34Ab1, Cry35Ab1, PAT, CP4
EPSPS and AAD-1 in the ﬁve-event stack maize.
Testing of new constituents other than newly expressed proteins
No new constituents other than newly expressed proteins have been identiﬁed in the ﬁve-event
stack maize. Therefore, no further food and feed safety assessment of components other than the
newly expressed proteins is required.
Information on altered levels of food and feed constituents
Protein, glutamic acid, glycine, leucine, lysine, threonine, magnesium and manganese in grain were
signiﬁcantly different in the ﬁve-event stack maize when compared to its comparator and showed lack
of equivalence with the set of non-GM reference varieties (see Section 3.3.2.3). Taking into account
the known biological role of these compounds, these differences are considered of no toxicological
concern by the GMO Panel. Further information on the safety of these maize constituents is provided
in Section 3.3.3.5.
Testing of the whole genetically modiﬁed food and feed
Based on the outcome of the studies considered in the molecular characterisation and comparative
analysis, no substantial modiﬁcations of toxicological relevance in the composition of the ﬁve-event
stack maize, and no indication of possible unintended effects relevant to food and feed safety have
been identiﬁed (see Sections 3.3.1 and 3.3.2.3). Therefore, animal studies on food and feed from the
ﬁve-event stack maize are not necessary (EFSA GMO Panel, 2011a).
3.3.3.4. Allergenicity
For the allergenicity assessment, a weight-of-evidence approach was followed, taking into account
all of the information obtained on the newly expressed proteins, as no single piece of information or
experimental method yields sufﬁcient evidence to predict allergenicity (Codex Alimentarius, 2009; EFSA
GMO Panel, 2011a). In addition, when known functional aspects of the newly expressed protein or
structural similarity to known adjuvants may indicate an adjuvant activity, the possible role of these
proteins as adjuvants is considered. When newly expressed proteins with a potential adjuvant activity
are expressed together, possible interactions increasing adjuvanticity and impacting the allergenicity of
the GM crop are assessed.
Assessment of allergenicity of the newly expressed protein
For allergenicity, the GMO Panel has previously evaluated the safety of Cry1A.105, Cry2Ab2, Cry1F,
Cry3Bb1, Cry34Ab1, Cry35Ab1, PAT, CP4 EPSPS and AAD-1 proteins individually, and no concerns on
allergenicity were identiﬁed in the context of the applications assessed (see Table 2). No new
information on allergenicity of these proteins that might change the previous conclusions of the GMO
Panel has become available. Based on the current knowledge, and as none of the newly expressed
proteins showed allergenicity, no reasons for concerns regarding the simultaneous presence of these
newly expressed proteins in the ﬁve-event stack maize affecting their allergenicity are expected.
For adjuvanticity, Cry1Ac protein has been suggested to possess adjuvant activity based on animal
studies when applied at relatively high doses (e.g. Vazquez et al., 1999). The Panel has previously
evaluated the safety of the Cry1A.105, Cry2Ab2, Cry1F, Cry3Bb1, Cry34Ab1 and Cry35Ab1 proteins and
no concerns on adjuvanticity were identiﬁed in the context of the applications assessed (see Table 2).
The levels of individual Bt proteins in the ﬁve-event stack maize are similar to those evaluated in the
four-event stack MON 89034 9 1507 9 MON 88017 9 DAS-59122-7 (see Appendix A). From the
limited evidence available, the GMO Panel did not ﬁnd indications that the presence of the Cry proteins
at the levels expressed in the ﬁve-event stack maize might act as adjuvants with the potential to
enhance a speciﬁc immunoglobulin E (IgE) response and to favour the development of an allergic
reaction.
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Assessment of allergenicity of the whole GM plant
The GMO Panel regularly reviews the available publications on food allergy to maize. However, to
date, maize has not been considered to be a common allergenic food17 (OECD, 2002). Therefore, the
GMO Panel did not request experimental data to analyse the allergen repertoire of GM maize.
In the context of this application and considering the data from the molecular characterisation, the
compositional analysis and the assessment of the newly expressed proteins (see Sections 3.3.1, 3.3.2
and 3.3.3), the GMO Panel identiﬁes no indications of a potentially increased allergenicity of foods and
feeds from the ﬁve-event stack maize with respect to those from its non-GM comparator.
3.3.3.5. Nutritional assessment of GM food and feed
The intended trait of the ﬁve-event stack maize is insect resistance and herbicide tolerance, with no
intention to alter the nutritional parameters. However, levels of protein, glutamic acid, glycine, leucine,
lysine, threonine, magnesium and manganese in grains from the ﬁve-event stack maize were
signiﬁcantly different from its non-GM comparator and showed a lack of equivalence with the set of
non-GM reference varieties (Section 3.3.2.3). The biological role of these compounds, the contribution
of maize to their total intake and the magnitude and direction of the observed changes are considered
in the nutritional assessment.
Human nutrition
A relatively small increase of protein content (3–6% as compared to its non-GM comparator) was
observed in the GM-maize what does not imply any concern from nutritional point of view. Maize
protein is considered of low nutritional quality due to a poor balance of essential amino acids, in
particular due to the low levels of lysine and tryptophan. Among the ﬁve amino acids where signiﬁcant
differences were observed as compared to its non-GM comparator, two of them are essential amino
acids: lysine and threonine. A decrease of approximately 1% and 5% in their relative amounts
(expressed as percentage of total amino acids) was observed for threonine and lysine, respectively.
Lysine is already a limiting amino acid in conventional maize while the amount of threonine present in
maize protein represents 157% of the requirements of this essential amino acid (FAO/WHO/UNU,
2007). Although this implies that the GM maize protein might be slightly poorer in amino acid
composition than the conventional one, the higher amount of protein in the GM maize indicates a
similar intake of these essential amino acids per amount of maize consumed. Therefore, the nutritional
impact of GM maize is considered the same as that of the non-GM comparator.
Increases up to 8% in manganese and up to 11% in magnesium were observed in the GM maize
as compared to its non-GM comparator. These two minerals are essential elements for humans and
Adequate Intakes (AI) have been proposed (EFSA, 2017a,b). While no Tolerable Upper Intake Levels
(UL) are set for manganese, for magnesium the UL refer to dissociable Mg salts (e.g. chloride, sulfate,
aspartate, lactate) and compounds like MgO in food supplements, in water or added to foods.
However, this UL does not include magnesium normally present in foods and beverages. In maize,
several minerals including manganese and magnesium are usually bound to phytic acid what decreases
substantially their bioavailability (Gupta et al., 2015; Suri and Tanumihardjo, 2016). Therefore, the
increase observed in these two essential elements does not represent any concern from nutritional
point of view.
Animal nutrition
Glutamic acid and glycine are not essential amino acids; the magnitude of their respective increase
and decrease in maize grains does not pose an issue for animal nutrition. Leucine, lysine and threonine
are essential amino acids; the increase observed in leucine in maize grains is not a problem for animal
nutrition. The magnitude of the decrease in lysine and threonine in maize grains does not pose a
problem for animal nutrition; these amino acids are usually balanced and supplemented in the
complete diets (e.g. monogastric animals). Maize grains are not considered a major source of proteins
in animals and the increase observed does not pose an issue for animals; it improves the protein
energy ratio in maize.
17 Regulation (EU) No 1169/2011 of the European Parliament and of the Council of 25 October 2011 on the provision of food
information to consumers, amending Regulations (EC) No 1924/2006 and (EC) No 1925/2006 of the European Parliament and
of the Council, and repealing Commission Directive 87/250/EEC, Council Directive 90/496/EEC, Commission Directive 1999/10/
EC, Directive 2000/13/EC of the European Parliament and of the Council, Commission Directives 2002/67/EC and 2008/5/EC
and Commission Regulation (EC) No 608/2004.
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Among minerals, magnesium and manganese are respectively considered major and trace elements
important in animal nutrition; the observed changes do not pose an issue for animals, since complete
diets are balanced with mineral premixes. Moreover, maize grains are also considered a poor source of
manganese (McDonald et al., 2011).
Conclusion on human and animal nutrition
Based on the current knowledge on the biological role of the compounds assessed, the magnitude
and direction of the changes identiﬁed, and the relevance of maize as contributor to the intake of
these compounds, the GMO Panel concludes that the nutritional impact of foods and feeds from the
ﬁve-event stack maize is expected to be the same as those from the comparator and non-GM
reference varieties.
3.3.3.6. Conclusion on food and feed safety assessment
The individual proteins Cry1A.105, Cry2Ab2, PAT, Cry1F, Cry3Bb1, CP4-EPSPS, Cry34Ab1, Cry35Ab1
and AAD-1 newly expressed in the ﬁve-event stack maize do not raise safety concerns for human and
animal health. Interactions between these newly expressed proteins raising food and feed safety
concerns (toxicological, allergenicity and adjuvanticity) are not expected. The nutritional impact of the
ﬁve-event stack maize foods and feeds is expected to be the same as those from the non-GM
comparator and non-GM reference varieties. The GMO Panel concludes that the ﬁve-event stack maize,
as described in this application, is as safe as and nutritionally equivalent to the non-GM comparator
and the non-GM reference varieties tested.
3.3.4. Environmental risk assessment18
Considering the scope of application EFSA-GMO-NL-2013-113, which excludes cultivation, the
environmental risk assessment (ERA) of the ﬁve-event stack maize mainly takes into account: (1) the
exposure of microorganisms to recombinant DNA in the gastrointestinal tract of animals fed GM
material and of microorganisms present in environments exposed to faecal material of these animals
(manure and faeces); and (2) the accidental release into the environment of viable ﬁve-event stack
maize grains during transportation and/or processing (EFSA GMO Panel, 2010a).
3.3.4.1. Persistence and invasiveness of the GM plant
Maize is highly domesticated, not winter hardy in colder regions of Europe, and generally unable to
survive in the environment without appropriate management. Occasional feral GM maize plants may
occur outside cultivation areas in the EU (e.g. Pascher, 2016), but survival is limited mainly by a
combination of low competitiveness, the absence of a dormancy phase and susceptibility to plant
pathogens, herbivores and cold climate conditions (OECD, 2003). Field observations indicate that
maize grains may survive and overwinter in some EU regions, resulting in volunteers in subsequent
crops (e.g. Gruber et al., 2008; Palaudelmas et al., 2009; Pascher, 2016). However, maize volunteers
have been shown to grow weakly and ﬂower asynchronously with the maize crop (Palaudelmas et al.,
2009). Thus, the establishment and survival of feral and volunteer maize in the EU is currently limited
and transient.
It is unlikely that the intended traits of the ﬁve-event stack maize and the observed difference in
disease incidence (see Section 3.3.2.2) will provide a selective advantage to maize plants, except when
they are exposed to glyphosate-, glufosinate-ammonium-, 2,4-D-containing herbicides or certain AOPP
herbicides (such as quizalofop), or infested by insect pests that are susceptible to the Cry1A.105,
Cry1F, Cry2Ab2, Cry34Ab1, Cry35Ab1 or Cry3Bb1 proteins. However, this ﬁtness advantage will not
allow the ﬁve-event stack maize to overcome other biological and abiotic factors (described above)
limiting plant’s persistence and invasiveness. Therefore, the presence of the intended traits will not
affect the persistence and invasiveness of the GM plant.
In conclusion, the GMO Panel considers it very unlikely that the ﬁve-event stack maize will differ
from conventional maize hybrid varieties in its ability to survive until subsequent seasons, or to
establish occasional feral plants under European environmental conditions in case of accidental release
into the environment of viable ﬁve-event stack maize grains.
18 Dossier: Part II Scientiﬁc information, Sections E3.1, E.3.2., D 9.4., D 9.5., D 9.8.
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3.3.4.2. Potential for gene transfer
A prerequisite for any gene transfer is the availability of pathways for the transfer of genetic
material, either through HGT of DNA, or through vertical gene ﬂow via cross-pollination from feral
plants originating from spilled grains.
Plant-to-microorganism gene transfer
The probability and potential adverse effects of HGT of the recombinant DNA have been assessed
in previous GMO Panel scientiﬁc opinions for the single events (see Table 2). No concern as a result of
an unlikely, but theoretically possible, HGT of the recombinant genes to bacteria in the gut of
domesticated animals and humans fed GM material or other receiving environments was identiﬁed.
The applicant submitted an updated bioinformatic analysis for each of the single events in order to
assess the possibility for HGT by homologous recombination.
The updated bioinformatic analysis for maize event 1507 revealed sufﬁcient length and sequence
identity for homologous recombination for two copies of the ORF25 terminator with the same A.
tumefaciens genomic sequence. Because of its length (~ 700 bp) and the opposite orientation of the
two ORF25 copies in maize event 1507, a potential for a facilitated HGT by double homologous
recombination (DHR) is unlikely. The occurrence of a DHR would result in the insertion of the pat gene
cassette which is expected to be less efﬁciently translated in potential bacterial recipients because of
the plant-codon optimisation of the pat gene and because the pat gene is under the control of plant
virus element.
The updated bioinformatic analyses for maize events MON 89034, MON 88017 and 59122 do not
reveal any new DNA sequence that could provide sufﬁcient length and identity which could facilitate
HGT by DHR, conﬁrming the previous conclusions (EFSA GMO Panel, 2017b,c).
Bioinformatic analysis for maize event DAS-40278-9 does not reveal sufﬁcient length and sequence
identity with known sequences from bacteria which would facilitate homologous recombination.
Synergistic effects of the recombinant genes, for instance due to combinations of recombinogenic
sequences, which would cause an increase in the likelihood for HGT or a selective advantage were not
identiﬁed.
Therefore, the GMO Panel concludes that the unlikely, but theoretically possible, horizontal transfer
of recombinant genes from this ﬁve-event stack maize to bacteria does not raise any environmental
safety concern.
Plant-to-plant gene transfer
The potential for occasional feral ﬁve-event stack maize plants originating from grain import spills
to transfer recombinant DNA to sexually compatible plants and the environmental consequences of this
transfer were considered.
For plant-to-plant gene transfer to occur, imported GM maize grains need to germinate and develop
into plants in areas containing sympatric wild relatives and/or cultivated maize with synchronous
ﬂowering and environmental conditions favouring cross-pollination.
Maize is an annual predominantly cross-pollinating crop. Cross-fertilisation occurs mainly by wind
(OECD, 2003). Vertical gene transfer from maize is limited to Zea species. Wild relatives of maize
outside cultivation are not known/reported in Europe (Eastham and Sweet, 2002; OECD, 2003; EFSA,
2016; Trtikova et al., 2017). Therefore, potential vertical gene transfer is restricted to maize and
weedy Zea species, such as teosintes, and/or maize-teosinte hybrids, occurring in cultivated areas
(EFSA, 2016; Trtikova et al., 2017).
The potential of spilled maize grains to establish, grow and produce pollen is extremely low and
transient (see Section 3.3.4.1). Therefore, the likelihood/frequency of cross-pollination between
occasional feral GM maize plants resulting from grain spillage, and weedy or cultivated Zea plants is
considered extremely low (EFSA, 2016). Even if cross-pollination would occur, the GMO Panel is of the
opinion that environmental effects as a consequence of the spread of genes from occasional feral GM
maize plants in Europe will not differ from that of conventional maize varieties for the reasons given in
Section 3.3.4.1, even if exposed to the intended herbicides.
3.3.4.3. Interactions of the GM plant with target organisms
Taking the scope of application EFSA-GMO-NL-2013-113 into account (no cultivation), potential
interactions of occasional feral the ﬁve-event stack maize plants arising from grain import spills with
target organisms are not considered a relevant issue.
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3.3.4.4. Interactions of the GM plant with non-target organisms
Given that environmental exposure of non-target organisms to spilled GM grains or occasional feral
GM maize plants arising from spilled ﬁve-event stack maize grains is limited, and because ingested
proteins are degraded before entering the environment through faecal material of animals fed GM
maize, potential interactions of the ﬁve-event stack maize with non-target organisms are not
considered to raise any environmental safety concern. Interactions that may occur between the Cry
proteins would not alter this conclusion.
3.3.4.5. Interactions with abiotic environment and biogeochemical cycles
Given that environmental exposure to spilled grains or occasional feral ﬁve-event stack maize plants
arising from grain import spills is limited, and because ingested proteins are degraded before entering
the environment through faecal material of animals fed GM maize, potential interactions with the
abiotic environment and biogeochemical cycles are not considered to raise any environmental safety
concern.
3.3.4.6. Conclusion on environmental risk assessment
The GMO Panel concludes that it is unlikely that the ﬁve-event stack maize would differ from
conventional maize varieties in its ability to persist under EU environmental conditions. Considering the
scope of application EFSA-GMO-NL-2013-113, interactions of occasional feral ﬁve-event stack maize
plants with the biotic and abiotic environment are not considered to be relevant issues. The analysis of
HGT from the ﬁve-event stack maize to bacteria does not indicate a safety concern. Therefore,
considering the combined traits and their interactions, the outcome of the comparative analysis, and
the routes and levels of exposure, the GMO Panel concludes that the ﬁve-event stack maize would not
raise safety concerns in the event of accidental release of viable GM maize grains into the
environment.
3.3.5. Conclusion on the ﬁve-event stack maize MON 89034 3 1507 3
MON 88017 3 59122 3 DAS-40278-9
No new data on the single maize events MON 89034, 1507, MON 88017, 59122 and DAS-40278-9
leading to a modiﬁcation of the original conclusions on their safety are identiﬁed.
The molecular characterisation, comparative analysis (agronomic, phenotypic and compositional
characteristics) and the outcome of the toxicological, allergenicity and nutritional assessment indicates
that the combination of the single maize events and of the newly expressed proteins in the ﬁve-event
stack maize does not give rise to food and feed safety and nutritional concerns. The GMO
Panel concludes that the ﬁve-event stack maize, as described in this application, is as safe as and
nutritionally equivalent to its non-GM comparator and the non-GM reference varieties tested.
Considering the combined traits and their interactions, the outcome of the comparative analysis,
and routes and levels of exposure, the GMO Panel concludes that the ﬁve-event stack maize would not
raise safety concerns in the event of accidental release of viable GM maize grains into the
environment.
No scientiﬁc information that could change the conclusions on this ﬁve-event stack was retrieved in
a literature search covering the period since the time of validity of the application.19
In conclusion, the GMO Panel considers that the ﬁve-event stack maize is as safe as its non-GM
comparator and the tested non-GM maize reference varieties with respect to potential effects on
human and animal health and the environment.
3.4. Risk assessment of the subcombinations20
Subcombinations previously assessed in the frame of other applications are discussed in
Section 3.4.1.
The strategy followed for the assessment of those subcombinations for which no speciﬁc data have
been submitted and which have not been previously assessed by the GMO Panel (see Table 8), has
been described by the GMO Panel.21 In this case, the risk assessment takes as its starting point the
assessment of the single maize events, and uses the data generated for the ﬁve-event stack, as well
19 Additional information: 22/12/2017.
20 Additional information: 22/3/2018, 18/6/2018.
21 115th GMO Panel meeting (Annex 1 of the minutes: https://www.efsa.europa.eu/sites/default/files/event/170517-m.pdf).
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as all the additional data available on subcombinations previously assessed by the GMO Panel (see
Table 2).
3.4.1. Subcombinations previously assessed
The GMO Panel has previously assessed 11 subcombinations (six-two-event stacks, four-three-event
stacks and one-four-event stack, see Table 2) and did not identify any safety concerns. No scientiﬁc
information relevant to the risk assessment of these maize stacks became available since the validation
of application EFSA-GMO-NL-2013-113. Consequently, the GMO Panel considers that its previous
conclusions on these subcombinations remain valid.
3.4.2. Subcombinations not previously assessed
Fourteen subcombinations included in the scope of this application have not been previously
assessed by the GMO Panel, and no experimental data were provided for these maize stacks (see
Table 8).
3.4.2.1. Stability of the events
The genetic stability of the inserted DNA over multiple generations in the ﬁve single maize events
has been demonstrated previously (see Table 2). Integrity of the events has been demonstrated in the
ﬁve-event stack maize (Section 3.3.1.2) and the previously assessed maize subcombinations (see
Table 2). The GMO Panel ﬁnds no reasons to expect loss of integrity of the events in the maize
subcombinations not previously assessed (see Table 8).
3.4.2.2. Expression of the events
The GMO Panel assessed whether any combination of any of the ﬁve events by conventional
crossing could result in signiﬁcant changes in expression levels of the newly expressed proteins, as this
could indicate an unexpected interaction between the events. Based on current knowledge of the
molecular elements introduced, there is no reason to expect interactions that would affect the levels of
the newly expressed proteins in the subcombinations compared with those in the single maize events.
This assumption is further supported in previous GMO Panel assessments for instance in two-event
maize stack MON89034 x MON88017 where it was concluded that the expression levels of Cry1A.105,
Cry2Ab2, Cry3Bb1, and CP4 EPSPS proteins in the stacked line were comparable to those in the single
events (EFSA, 2010). Similar conclusion was drawn for proteins Cry34Ab1, Cry35Ab1, Cry1F and PAT
when assessing the two-event maize stack 1507 9 59122 (EFSA, 2009c). Furthermore, in the
assessment of the four-event maize stack MON 89034 9 1507 9 MON 88017 9 59122, the GMO
Panel concluded that the expression levels of proteins Cry1A.105, Cry2Ab2, Cry1F, PAT, Cry3Bb1, CP4
Table 8: Subcombinations of maize MON 89034 9 1507 9 MON 88017 9 59122 9 DAS-40278-9
not previously assessed and covered by the scope of application EFSA-GMO-NL-2013-113
Degree of stacking Events
Four-event stack maize MON 89034 9 1507 9 MON 88017 9 DAS-40278-9
MON 89034 9 1507 9 59122 9 DAS-40278-9
MON 89034 9 MON 88017 9 59122 9 DAS-40278-9
1507 9 MON 88017 9 59122 9 DAS-40278-9
Three-event stack maize MON-89034 9 MON 88017 9 DAS-40278-9
MON-89034 9 59122 9 DAS-40278-9
MON 89034 9 1507 9 DAS-40278-9(a)
1507 9 MON 88017 9 DAS-40278-9
1507 9 59122 9 DAS-40278-9
MON 88017 9 59122 9 DAS-40278-9
Two-event stack maize MON 88017 9 DAS-40278-9
MON-89034 9 DAS-40278-9(a)
1507 9 DAS-40278-9(a)
59122 9 DAS-40278-9
(a): Subcombinations assessed in parallel in the context of application EFSA-GMO-NL-2013-112 (EFSA GMO Panel, 2019).
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EPSPS, Cry34Ab1 and Cry35Ab1 are comparable to those in the single events (EFSA GMO Panel,
2010c). This conﬁrms that interactions affecting expression levels of the newly expressed proteins are
not expected in the 14 maize subcombinations not previously assessed and included in the scope of
application EFSA-GMO-NL-2013-113.
3.4.2.3. Potential functional interactions between the events
The GMO Panel assessed the potential for interactions between maize events in the
subcombinations not previously assessed (Table 8), taking into consideration intended traits and
unintended effects.
Based on the known biological functions of the individual newly expressed proteins (Table 4), there
is currently no expectation for possible interactions relevant for the food and feed or environmental
safety between these proteins in the 14 subcombinations not previously assessed. The GMO Panel took
into account all the intended and potential unintended effects considered in the assessment of the ﬁve
single events, the previously assessed subcombinations (Table 2) and the ﬁve-event stack maize. It is
concluded that none of these effects would raise safety concerns when combined in any of these
maize subcombinations. Therefore, the GMO Panel is of the opinion that no additional data are needed
to complete the assessment of subcombinations from the ﬁve-event stack maize.
3.4.3. Conclusion
Since no new safety concerns were identiﬁed for the previously assessed 11 subcombinations (six-
two-event stacks, four-three-event stacks and one-four-event stack), the GMO Panel considers that its
previous conclusions on these maize subcombinations remain valid. For the remaining 14
subcombinations included in the scope of application EFSA-GMO-NL-2013-113 for which no
experimental data have been provided, the GMO Panel has assessed the possibility of interactions
between the events and concludes that these combinations would not raise safety concerns. These
subcombinations are therefore expected to be as safe as and nutritionally equivalent to the single
maize events, the previously assessed 11 subcombinations as well as the ﬁve-event stack maize.
3.5. Post-market monitoring22
3.5.1. Post-market monitoring of GM food/feed
The GMO Panel concludes that the ﬁve-event stack maize, as described in this application, is
nutritionally equivalent to and as safe as the non-GM comparator and the non-GM reference varieties
tested, and no post-market monitoring (EFSA GMO Panel, 2011a) of food and feed is considered
necessary.
Eleven subcombinations (six-two-event stacks, four-three-event stacks and one-four-event stack,
see Table 2) have been previously assessed and no safety concerns were identiﬁed. The 14
subcombinations not previously assessed and included in the scope of application EFSA-GMO-NL-2013-
13 are expected to be as safe as and nutritionally equivalent to the single maize events, the previously
assessed maize subcombinations and the ﬁve-event stack maize. Therefore, the GMO Panel considers
that post-market monitoring of the ﬁve-event stack maize and its subcombinations, as described in this
application, is not necessary.
3.5.2. Post-market environmental monitoring
The objectives of a post-market environmental monitoring (PMEM) plan, according to Annex VII of
Directive 2001/18/EC, are: (1) to conﬁrm that any assumption regarding the occurrence and impact of
potential adverse effects of the GMO, or its use, in the ERA are correct; and (2) to identify the
occurrence of adverse effects of the GMO, or its use, on human health or the environment that were
not anticipated in the ERA.
Monitoring is related to risk management, and thus a ﬁnal adoption of the PMEM plan falls outside
the mandate of EFSA. However, the GMO Panel gives its opinion on the scientiﬁc rationale of the PMEM
plan provided by the applicant (EFSA GMO Panel, 2011b).
As the ERA did not identify potential adverse environmental effects from the ﬁve-event stack maize,
no case-speciﬁc monitoring is required.
22 Dossier: Part II – Section D and E4; additional information: 13/12/2016.
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The PMEM plan proposed by the applicant for the ﬁve-event stack maize and its subcombinations
includes: (1) the description of a monitoring approach involving operators (federations involved in
import and processing), reporting to the applicant, via a centralised system, any observed adverse
effect(s) of GMOs on human health and the environment; (2) a coordinating system established by
EuropaBio for the collection of information recorded by the various operators; and (3) the review of
relevant scientiﬁc publications retrieved from literature searches (Lecoq et al., 2007; Windels et al.,
2008). The applicant proposes to submit a PMEM report on an annual basis and a ﬁnal report at the
end of the authorisation period.
The GMO Panel considers that the scope of the PMEM plan provided by the applicant is consistent
with the intended uses of the ﬁve-event stack maize. The GMO Panel agrees with the reporting
intervals proposed by the applicant in its PMEM plan. The PMEM plan and reporting intervals are in line
with the intended uses of the ﬁve-event stack maize and its subcombinations.
3.5.3. Conclusion on post-market monitoring
No post-market for food and feed is necessary. The scope of the PMEM plan provided by the
applicant and the reporting intervals are in line with the intended uses of the ﬁve-event stack maize
and its subcombinations.
4. Overall conclusions and recommendations
No new data on the ﬁve single maize events MON 89034, 1507, MON 88017, 59122 and DAS-
40278-9 that would lead to a modiﬁcation of the original conclusions on their safety are identiﬁed.
The molecular characterisation, comparative analysis (agronomic, phenotypic and compositional
characteristics) and the outcome of the toxicological, allergenicity and nutritional assessment indicate
that the combination of the single maize events and of the newly expressed proteins in the ﬁve-event
stack maize does not give rise to food and feed safety and nutritional concerns. The GMO
Panel concludes that the ﬁve-event stack maize, as described in this application, is as safe as and
nutritionally equivalent to its non-GM comparator and the non-GM reference varieties tested, and no
post-market monitoring of food and feed is considered necessary.
The GMO Panel concludes that there is a very low likelihood of environmental effects resulting from
the accidental release of viable grains from ﬁve-event stack maize into the environment.
Since no new data on the 11 subcombinations (six-two-event stacks, four-three-event stacks and
one-four-event stack) previously assessed that would lead to a modiﬁcation of the original conclusions
on their safety are identiﬁed, the GMO Panel considers that its previous conclusions on these maize
stacks remain valid.
For the additional 14 maize subcombinations included in the scope of application EFSA-GMO-NL-
2013-113 for which no experimental data have been provided, the GMO Panel assessed possible
interactions between the events, and concludes that combinations of maize events MON 89034, 1507,
MON 88017, 59122 and DAS-40278-9 would not raise safety concerns in these maize subcombinations.
These subcombinations are therefore expected to be as safe as and nutritionally equivalent to the
maize single events, the previously assessed subcombinations and the ﬁve-event stack maize.
Given the absence of safety concerns for foods and feeds from the ﬁve-event stack maize and all
its subcombinations, the GMO Panel considers that post-market monitoring of these products is not
necessary.
The PMEM plan provided by the applicant and the reporting intervals are in line with the intended
uses of the ﬁve-event stack maize and its subcombinations.
Documentation provided to EFSA
1) Application EFSA-GMO-NL-2013-113 received from the Competent Authority of Netherlands in
support to Dow AgroSciences request for placing maize MON 89034 9 1507 9 MON
88017 9 59122 9 DAS-40278-9 on the EU market according to Regulation (EC) No 1829/2003,
6 February 2013.
2) Receipt of application EFSA-GMO-NL-2013-113 acknowledged by EFSA, 28 February 2013.
3) Application EFSA-GMO-NL-2013-113 validated by EFSA, 2 October 2014.
4) Receipt of spontaneous information from the applicant, 24 April 2015.
5) Request for supplementary information to the applicant, 11 August 2016.
6) Receipt of supplementary information from the applicant, 13 October 2016.
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7) Request for supplementary information to the applicant, 3 November 2016.
8) Request for supplementary information to the applicant, 9 November 2016.
9) Request for supplementary information to the applicant, 21 December 2016.
10) Receipt of supplementary information from the applicant, 24 January 2017.
11) Request for supplementary information to the applicant, 27 January 2017.
12) Receipt of supplementary information from the applicant, 7 February 2017.
13) Receipt of supplementary information from the applicant, 6 March 2017.
14) Request for supplementary information to the applicant, 14 March 2017.
15) Request for supplementary information to the applicant, 11 April 2017.
16) Request for supplementary information to the applicant, 18 May 2017.
17) Receipt of supplementary information from the applicant, 8 June 2017.
18) Receipt of supplementary information from the applicant, 19 September 2017.
19) Request for supplementary information to the applicant, 25 September 2017.
20) Receipt of supplementary information from the applicant, 23 November 2017.
21) Receipt of supplementary information from the applicant, 22 December 2017.
22) Request for supplementary information to the applicant, 17 January 2018.
23) Receipt of supplementary information from the applicant, 18 January 2018.
24) Receipt of supplementary information from the applicant, 12 March 2018.
25) Request for supplementary information to the applicant, 22 March 2018.
26) Request for supplementary information to the applicant, 4 May 2018.
27) Receipt of supplementary information from the applicant, 7 May 2018.
28) Request for supplementary information to the applicant, 18 June 2018.
29) Request for supplementary information to the applicant, 29 August 2018.
30) Receipt of supplementary information from the applicant, 20 September 2018.
31) Receipt of supplementary information from the applicant, 10 October 2018.
32) Receipt of supplementary information from the applicant, 20 November 2018.
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Abbreviations
2,4-D 2,4-dichlorophenoxyacetic acid
AAD-1 aryloxyalkanoate dioxygenase 1
ADF acid detergent ﬁbre
AI Adequate Intakes
AOPP aryloxyphenoxypropionate
CTP chloroplast transit peptide
cry crystal protein
DHR double homologous recombination
dw dry weight
ELISA enzyme-linked immunosorbent assay
EPSPS 5-enolpyruvylshikimate-3-phosphate synthase
ERA environmental risk assessment
GM genetically modiﬁed
GMO genetically modiﬁed organism
GMO Panel EFSA Panel on Genetically Modiﬁed Organisms
HGT horizontal gene transfer
IgE immunoglobulin E
NDF neutral detergent ﬁbre
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OECD Organisation for Economic Co-operation and Development
ORF open reading frame
PAT phosphinothricin acetyltransferase
PMEM post-market environmental monitoring
PPP plant protection products
TDF total detergent ﬁbre
UL tolerable upper intake levels
UTR untranslated region
WSR Wilcoxon signed-rank
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Appendix A – Protein expression data
Mean, standard deviation and range of protein levels (lg/g dry weight) from maize MON
89034 9 1507 9 MON 88017 9 59122 9 DAS-40278-9, MON 89034 9 1507 9 MON 88017 9 DAS-
59122-7, and DAS‑402789 unsprayed tissues from ﬁeld trials performed across 10 locations in the US
in 2010 (n = 40)
DAS-
40278-9
MON 89034 3 1507 3 MON
88017 3 DAS-59122-7
MON 89034 3 1507 3 MON 88017 3
59122 3 DAS-40278-9
Cry1A.105
Leaf V2–V4 196.56  64.09 (104.14–296.10) 190.28  70.49 (80.50–284.70)
Leaf V9 56.85  24.76 (33.30–118.81) 65.39  25.93 (37.49–123.81)
Leaf R1 38.43  14.50 (23.14–65.61) 40.38  16.25 (20.45–75.65)
Root R1 17.22  4.83 (10.01–24.32) 19.47  5.59 (11.69–25.86)
Forage R4 27.24  10.42 (10.03–45.78) 22.90  6.71 (14.47–30.79)
Whole plant R6 8.90  3.47 (5.08–16.09) 7.55  2.89 (4.66–14.69)
Pollen R1 17.10  2.01 (12.96–20.18) 17.08  1.20 (14.63–18.49)
Grain R6 5.62  0.74 (4.44–6.73) 4.96  0.77 (4.15–6.56)
Cry2Ab2
Leaf V2–V4 161.39  35.06 (108.60–211.50) 150.88  56.61 (90.00–279.67)
Leaf V9 70.19  16.98 (44.58–104.64) 69.68  18.23 (43.23–107.05)
Leaf R1 64.22  28.77 (25.00–115.23) 64.73  26.66 (24.18–120.09)
Root R1 36.35  12.57 (18.82–53.25) 40.43  17.67 (20.62–69.29)
Forage R4 39.80  9.42 (29.45–52.33) 38.52  9.55 (25.25–51.10)
Whole plant R6 22.72  12.56 (7.74–47.68) 20.67  9.82 (7.43–38.79)
Pollen R1 0.52  0.11 (0.37–0.71) 0.54  0.14 (0.36–0.78)
Grain R6 2.66  0.40 (2.15–3.35) 2.73  0.67 (1.59–3.44)
Cry1F
Leaf V2–V4 21.29  8.43 (12.30–35.94) 21.74  10.30 (11.28–40.00)
Leaf V9 7.54  2.42 (5.28–12.59) 8.97  2.89 (5.73–14.06)
Leaf R1 7.38  3.25 (4.44–13.30) 8.12  3.50 (3.75–15.70)
Root R1 4.40  0.88 (3.05–5.85) 4.80  1.06 (3.63–6.47)
Forage R4 6.63  1.75 (4.17–10.58) 6.51  1.27 (5.23–9.47)
Whole plant R6 3.72  0.90 (2.51–5.14) 3.45  0.66 (2.61–4.77)
Pollen R1 14.43  1.72 (12.32–17.47) 13.97  1.63 (12.11–16.45)
Grain R6 2.43  0.16 (2.13–2.76) 2.38  0.28 (2.01–3.00)
Cry3Bb1
Leaf V2–V4 225.30  48.09 (170.27–306.50) 226.79  53.56 (152.13–312.50)
Leaf V9 112.25  18.58 (87.05–140.70) 108.31  16.51 (75.15–127.30)
Leaf R1 104.86  41.49 (60.55–176.25) 95.83  34.92 (53.75–165.85)
Root R1 67.82  15.83 (47.95–88.50) 68.54  17.44 (44.89–92.55)
Forage R4 66.44  8.96 (54.23–81.60) 63.55  8.02 (49.48–77.93)
Whole plant R6 23.05  6.88 (11.03–30.57) 20.88  5.87 (9.01–28.34)
Pollen R1 9.29  1.18 (7.26–10.63) 9.15  0.97 (8.05–10.91)
Grain R6 6.13  0.81 (4.83–7.30) 5.88  0.47 (5.30–6.71)
Cry34Ab1
Leaf V2–V4 86.31  28.52 (47.30–147.47) 81.82  26.84 (39.40–124.20)
Leaf V9 75.27  20.22 (39.50–105.38) 75.13  19.50 (39.50–102.20)
Leaf R1 116.96  35.80 (75.00–176.69) 127.57  46.75 (75.75–211.65)
Root R1 62.93  18.81 (42.10–90.93) 64.18  24.00 (34.78–94.01)
Forage R4 128.20  30.34 (78.50–190.77) 124.10  22.79 (96.85–166.79)
Whole plant R6 99.08  30.72 (64.50–149.26) 92.78  28.06 (58.10–130.00)
Pollen R1 78.12  27.93 (46.65–142.07) 74.60  27.70 (50.30–138.06)
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DAS-
40278-9
MON 89034 3 1507 3 MON
88017 3 DAS-59122-7
MON 89034 3 1507 3 MON 88017 3
59122 3 DAS-40278-9
Grain R6 44.04  7.18 (33.20–56.20) 41.30  5.94 (30.07–48.70)
Cry35Ab1
Leaf V2–V4 33.50  9.80 (22.77–52.90) 32.24  8.13 (21.37–46.35)
Leaf V9 37.36  14.20 (21.56–60.76) 38.50  12.82 (23.31–62.35)
Leaf R1 51.05  14.44 (37.00–88.45) 50.82  11.82 (36.45–75.00)
Root R1 7.19  1.59 (4.87–9.71) 6.93  1.94 (4.48–9.93)
Forage R4 17.64  2.41 (14.50–22.21) 16.98  2.23 (13.13–19.50)
Whole plant R6 9.26  4.72 (4.03–17.95) 8.35  4.57 (3.83–18.26)
Pollen R1 ND  NA (ND–0.14) ND  NA (ND–(0.04))
Grain R6 0.92  0.16 (0.62–1.14) 0.95  0.18 (0.73–1.21)
CP4 EPSPS
Leaf V2–V4 148.51  40.95 (80.55–218.70) 148.96  59.33 (69.75–253.13)
Leaf V9 92.50  22.39 (57.40–118.20) 108.24  40.16 (63.60–199.10)
Leaf R1 89.62  32.92 (56.30–168.80) 90.78  26.82 (56.00–139.80)
Root R1 22.56  5.17 (14.90–30.53) 22.86  7.17 (14.00–36.02)
Forage R4 37.95  3.27 (33.20–42.20) 36.54  2.70 (30.40–39.20)
Whole plant R6 12.88  8.17 (4.02–33.60) 10.57  5.63 (4.48–23.93)
Pollen R1 174.35  21.64 (135.30–201.25) 174.66  23.86 (145.20–230.15)
Grain R6 3.54  1.26 (2.77–7.06) 3.51  1.06 (2.61–6.27)
PAT
Leaf V2–V4 18.23  6.82 (7.61–26.66) 18.42  7.64 (7.46–30.41)
Leaf V9 13.19  6.46 (3.45–22.95) 15.11  6.10 (7.65–27.31)
Leaf R1 13.30  7.44 (4.23–29.33) 11.29  3.15 (6.84–16.25)
Root R1 0.57  0.26 (0.17–1.09) 0.58  0.25 (0.22–1.15)
Forage R4 1.21  0.58 (0.11–1.98) 1.10  0.53 (0.09–1.81)
Whole plant R6 0.10  0.06 ((0.05)–0.23) 0.06  0.03 (ND–0.13)
Pollen R1 ND  NA (ND–ND) ND  NA (ND–ND)
Grain R6 ND  0.03 (ND – 0.08) (0.03)  0.03 (ND – 0.07)
AAD-1
Leaf V2–V4 14.37  6.11
(5.84–24.61)
14.20  6.39 (6.01–23.73)
Leaf V9 6.60  0.96
(4.73–8.01)
7.42  3.04 (4.30–14.88)
Leaf R1 5.87  2.22
(2.80–9.65)
7.47  2.70 (4.66–11.67)
Root R1 2.69  1.42
(1.03–4.19)
3.46  2.12 (1.17–7.30)
Forage R4 6.84  2.33
(3.18–10.29)
6.74  2.46 (3.39–10.71)
Whole plant R6 3.31  1.66
(0.89–5.73)
2.53  1.16 (0.59–4.25)
Pollen R1 141.26  21.81
(94.68–165.47)
139.21  17.83 (103.64–159.20)
Grain R6 4.24  1.43
(2.57–6.57)
3.87  0.72 (2.64–4.95)
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